Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
3281680 | Clinical Gastroenterology and Hepatology | 2016 | 41 Pages |
Abstract
In a prospective study of patients with chronic GERD, esophageal acid reflux was reduced greatly by LARS or esomeprazole therapy. However, patients receiving LARS had significantly greater reductions in 24-hour esophageal acid exposure after 6 months and 5 years. Esophageal and gastric pH, off and on therapy, did not predict long-term outcomes of patients. Abnormal supine acid exposure predicted esomeprazole dose escalation. ClinicalTrials.Gov identifier: NCT00251927 (available: http://clinicaltrials.gov/ct2/show/NCT00251927).
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Gastroenterology
Authors
Jan G. Hatlebakk, Frank Zerbib, Stanislas Bruley des Varannes, Stephen E. Attwood, Christian Ell, Roberto Fiocca, Jean-Paul Galmiche, Stefan Eklund, Göran LÃ¥ngström, Tore Lind, Lars R. Lundell, LOTUS Study Group LOTUS Study Group,